查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2002907

肾臟神经阻断装置市场：2026-2032年全球市场预测（依产品类型、能源来源、手术、应用、最终用户及通路划分）

Renal Denervation Devices Market by Product Type, Energy Source, Procedure, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，肾臟神经阻断器设备市场价值将达到 3.0142 亿美元，到 2026 年将成长至 3.4211 亿美元，到 2032 年将达到 7.7174 亿美元，年复合成长率为 14.37%。

主要市场统计数据
基准年 2025 3.0142亿美元
预计年份：2026年 3.4211亿美元
预测年份 2032 7.7174亿美元
复合年增长率 (%) 14.37%

对不断发展的肾臟去神经装置趋势进行全面概述，重点关注临床整合、监管重点和程序创新。

肾臟去神经装置在介入性心臟病学、肾臟病学和微创治疗的交叉领域中占据着至关重要且不断发展的地位。过去十年间，装置结构、能量输送方式和手术流程的迭代改进，已将最初尚不成熟的手术概念转变为针对特定患者群体的可靠治疗选择。临床医生和医院系统越来越倾向于将肾臟去神经装置视为一套综合方法，而非单一技术，这需要严格的临床证据、可重复的手术流程以及从急性期护理团队到长期慢性病管理的整合式护理路径。

技术融合、临床证据的完善以及医疗服务模式的变革，是如何重新定义实施过程和设备设计的优先事项的？

肾臟神经消融领域正经历一场变革，这得益于技术进步、实证医学证据累积和医疗服务模式的整合发展。製造商不再局限于硬体的渐进式改进，而是致力于开发整合系统解决方案，将先进的能量传输技术与手术引导工具、影像辅助设备以及术后远端监测相结合。这些技术进步也得到了更完善的实证医学基础的支持。现代临床试验，透过改善患者选择标准、优化终点指标和进行长期随访，清楚地证实了肾臟神经消融在治疗高血压、心臟衰竭和肾功能损害方面具有显着的临床效益。

评估美国关税政策变化对医疗设备产品组合的供应链、定价谈判和区域製造策略的多方面影响。

美国关税的引入和贸易政策的变化正在对肾臟去神经装置生态系统产生连锁反应，影响製造策略、零件采购和商业性定价动态。随着关税的增加，进口零件和成品的成本上升，原始设备製造商 (OEM) 被迫在利润率下降、将额外成本转嫁给买家或重组供应链之间做出选择。为此，许多公司正在加快区域化生产、供应商多元化和替代零件来源认证的计划，而这些都需要资本投资和製造地的监管重新认证。

将产品模式、能量传输方式、应用、终端用户趋势、分销管道和治疗策略与商业性成果联繫起来的详细細項分析。

细分市场分析揭示了影响产品开发和市场进入策略的明确临床和商业性需求。根据产品类型，该领域包括能量型系统（包括单极和多极射频消融术）、化学消融术（例如乙醇消融术）以及采用血管内或体外给药方式的超音波系统。每种产品子类别都有不同的治疗需求、训练要求和资本投入，导致其在不同的临床环境中呈现不同的部署路径。

监管环境、临床基础设施和报销环境的区域趋势决定了实施管道和商业策略的差异。

区域趋势造就了不同的机会和限制因素，进而影响监管路径、临床应用和商业策略。在美洲，成熟的医保报销体系、完善的心肾介入医疗网络以及集中开展的临床试验活动，都为循证医学向临床实践的快速转化提供了支持。同时，整合医疗服务体系中的医疗购买者往往优先考虑医疗总成本和手术量。相较之下，欧洲、中东和非洲（EMEA）地区的监管核准流程和支付方参与度则有更大的差异。儘管领先的医疗中心正在推动临床应用，但各地区的报销时间不尽相同，且成本控制较为敏感，因此建议采用以卫生经济学证据和区域关键意见领袖（KOL）建议为重点的临床应用策略。

企业层面的策略行动着重于基于临床证据的差异化、一体化服务交付和弹性的製造结构，以加速产品采用和商业化。

医疗设备开发商和生态系统参与者的主要竞争策略集中在累积证据、打造差异化技术堆迭以及建立通路伙伴关係，以加速临床应用。产业领导企业优先进行随机临床试验项目，以清楚展现持续的治疗效果和最有效的患者亚群，同时投资新一代导管设计、能量调节演算法和辅助成像技术，以提高手术精准度。医疗设备开发商、临床研究机构和医疗系统之间的策略联盟日益普遍，从而推动了多中心註册研究和真实世界数据（RWE）计画的开展，这些计画能够补充主要临床试验，并加速与支付方的谈判。

为推动永续推广，提出切实可行的、多方面的建议，包括投资临床证据、供应链韧性、培训、商业化和支付方参与。

产业领导者应采取协调一致的策略，同步解决临床可靠性、供应链韧性和支付方参与度等问题。首先，投资于有针对性的临床项目，优化患者选择，并验证具有临床意义的终点指标，从而降低后续成本，进而促进与支付方的对话以及医疗机构的推广应用。其次，实现采购多元化，并考虑本地组装和製造，以降低关税风险、缩短前置作业时间，同时确保所有地区的品质系统和监管合规性。第三，在设计产品系列，应以营运效率为导向，促进门诊应用，减少医院资源消耗，并符合以价值为基础的采购模式。

采用透明的混合方法研究途径，结合系统证据审查、临床医生访谈和营运分析，得出检验的策略见解。

本执行摘要的研究基础是系统性文献整合、专家访谈以及对一手和二手资料的检验，以确保得出可靠且可操作的见解。该调查方法结合了对同行评审的临床研究、监管申报文件和公开的程序指南的全面审查，以及对介入性心臟病专家、肾臟病专家、医院采购经理和医疗设备业高管的结构化访谈，以识别实际实施中的挑战和驱动因素。研究汇总了医疗设备註册和程序审计的数据，以识别工作流程限制、医疗设备使用模式和培训瓶颈。此外，研究结果也透过与临床专家的后续咨询进行了交叉检验。

为确保永续采用和有效性，总结的结论强调了临床证据、营运准备和商业性可行性的协调。

本文提出的全面见解凸显了向差异化治疗平台转变的趋势，这需要整合临床证据、供应链和商业化等多个面向的策略。随着化学、射频和超音波等多种治疗手段的出现，器械类型日益多样化，相关人员必须专注于在明确界定的患者群体中证明其具有持续的临床益处，并使产品设计与实际治疗流程相契合。区域监管预期、支付方要求和临床经济学之间的相互作用将继续决定哪些技术最终能够进入常规临床应用。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 肾臟神经阻断装置市场：依产品类型划分

  • 化学
  • 高频
    • 单极
    • 多极型
  • 超音波
    • 血管内
    • 体外

第九章 肾臟神经阻断装置市场（依能源来源划分）

  • 化学
  • 高频
  • 超音波

第十章 肾臟神经阻断装置市场（依手术类型划分）

  • 双方
  • 一边

第十一章 肾臟神经阻断装置市场：依应用领域划分

  • 慢性肾臟病
  • 心臟衰竭
  • 高血压

第十二章 肾臟神经阻断装置市场：依最终用户划分

  • 门诊手术中心
  • 心臟中心
  • 诊所
  • 医院

第十三章 肾臟神经阻断装置市场：依通路划分

  • 直销
  • 销售代理

第十四章 肾臟神经阻断装置市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 肾臟神经阻断装置市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 肾臟神经阻断装置市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国肾神经阻断装置市场

第十八章：中国肾臟神经阻断装置市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Ablative Solutions, Inc.
  • AngioDynamics, Inc.
  • Biosense Webster, Inc.
  • Boston Scientific Corporation
  • Cardionovum GmbH
  • Cordis Corporation
  • DeepQure Inc.
  • Johnson & Johnson Services, Inc.
  • Medinol Ltd.
  • Medtronic plc
  • Mercator MedSystems, Inc.
  • Miracor Medical SA
  • Otsuka Medical Devices Co., Ltd.
  • ReCor Medical, Inc.
  • Renal Dynamics Ltd.
  • Shanghai Golden Leaf MedTec Co., Ltd.
  • Shanghai Wisegain Medical Devices Co., Ltd.
  • SoniVie Ltd.
  • SoundPipe Therapeutics LLC
  • Suzhou SyMap Medical Devices Co., Ltd.
  • Symap Medical Co., Ltd.
  • Symple Surgical, Inc.
  • Terumo Corporation
Product Code: MRR-957C47F91FC5

The Renal Denervation Devices Market was valued at USD 301.42 million in 2025 and is projected to grow to USD 342.11 million in 2026, with a CAGR of 14.37%, reaching USD 771.74 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 301.42 million
Estimated Year [2026] USD 342.11 million
Forecast Year [2032] USD 771.74 million
CAGR (%) 14.37%

Comprehensive introduction to the evolving renal denervation device landscape highlighting clinical convergence regulatory emphasis and procedural innovation

Renal denervation devices occupy a pivotal and evolving position at the intersection of interventional cardiology, nephrology, and minimally invasive therapeutics. Over the past decade, iterative advances in device architecture, energy delivery modalities, and procedural workflows have transformed a nascent procedural concept into a credible therapeutic option for select patient populations. Clinicians and hospital systems are increasingly evaluating renal denervation not as a single technology but as a portfolio of approaches that require rigorous clinical evidence, reproducible procedural techniques, and integrative care pathways that span acute procedural teams and longitudinal chronic disease management.

Regulatory agencies and professional societies have catalyzed this evolution by emphasizing randomized controlled evidence and standardized endpoints, while payers are beginning to articulate pathways for coverage that hinge on demonstrated clinical benefit and cost effectiveness. In parallel, manufacturers are responding with diversified product designs, from chemical ablation platforms to radiofrequency and ultrasound modalities, each targeting different anatomical approaches and procedural efficiencies. As a result, stakeholders across clinical practice, supply chain, and commercial strategy must recalibrate priorities to reflect a landscape defined by differentiated device capabilities, shifting reimbursement expectations, and growing demand for outpatient and ambulatory procedural settings. These dynamics frame the strategic considerations examined in the subsequent sections of this executive summary.

How technological convergence clinical evidence refinement and shifting care delivery models are redefining adoption pathways and device design priorities

The renal denervation landscape is experiencing transformative shifts driven by convergent advances in technology, evidence generation, and care delivery models. Manufacturers are moving beyond incremental hardware improvements and toward integrated system solutions that couple refined energy delivery with procedural guidance tools, imaging adjuncts, and postprocedure remote monitoring. These technical advances are complemented by a more sophisticated evidence base, where contemporary trials leverage improved patient selection criteria, refined endpoints, and longer follow up to articulate meaningful clinical benefits for hypertension, heart failure phenotypes, and renal impairment.

Concurrently, procedural migration toward ambulatory and ambulatory surgical center settings is reshaping device design priorities, with a premium on simplified workflows, shorter procedure times, and enhanced safety profiles. Payer dialogue has also evolved from a binary coverage decision to a nuanced discussion of value-based reimbursement, conditional coverage with evidence development, and bundled payment models tied to downstream outcomes. Geopolitical and supply chain considerations are prompting localized manufacturing and diversified supplier relationships to mitigate tariff exposure and component shortages. Together, these shifts are compressing time to adoption for systems that demonstrate clear procedural efficiency, reproducible outcomes, and scalable training models, while raising the bar for newcomers seeking commercial traction.

Assessing the multifaceted consequences of United States tariff shifts on supply chains pricing negotiations and regional manufacturing strategies for device portfolios

Introduction of tariffs and trade policy changes in the United States have a cascading impact on the renal denervation device ecosystem, affecting manufacturing strategies, component sourcing, and commercial pricing dynamics. When tariffs increase the landed cost of imported components or finished devices, original equipment manufacturers are faced with a choice between absorbing margin compression, passing incremental costs to purchasers, or reconfiguring supply chains. In response, many firms accelerate plans for regional production, supplier diversification, and qualification of alternate component sources, which in turn demand capital investment and regulatory revalidation of manufacturing sites.

Tariff-driven cost pressures also influence distributor strategies and contracting terms with hospital systems and ambulatory surgical centers, as procurement teams negotiate to preserve unit prices while assessing total cost of care. For some device categories, particularly those with high-cost consumables or software-enabled disposables, tariffs can shift the balance in favor of platforms with fewer imported components or with modular architectures that support local assembly. Over time, differential tariff exposure across product lines may shape portfolio decisions, prompting developers to prioritize device variants and procedural adjuncts that are less supply chain sensitive. Clinicians and institutional procurement teams should therefore anticipate an era where commercial availability and lead times are influenced as much by trade policy as by clinical evidence.

In depth segmentation insights linking product modalities energy delivery applications end user dynamics distribution channels and procedural strategies to commercial outcomes

Segmentation analysis reveals distinct clinical and commercial imperatives that influence product development and go to market approaches. Based on product type, the landscape comprises chemical modalities such as ethanol ablation alongside energy based systems including radiofrequency approaches differentiated into monopolar and multipolar architectures, and ultrasound systems that deploy either endovascular or external delivery methods. Each product subclass imposes different procedural requirements, training needs, and capital intensity, creating differentiated adoption trajectories across clinical settings.

Based on energy source, stakeholders evaluate efficacy and safety tradeoffs among chemical, radiofrequency, and ultrasound platforms, with energy modality informing catheter design, mapping needs, and postprocedure surveillance. Based on application, clinical deployment spans chronic kidney disease with stratification by early and advanced stages, heart failure with phenotypes characterized by preserved or reduced ejection fraction, and hypertension categorized into primary and secondary forms. These application niches dictate patient selection algorithms, trial endpoint design, and payer value propositions.

Based on end user, adoption patterns diverge across ambulatory surgical centers, cardiac centers, clinics, and hospitals, each setting presenting unique credentialing, inventory management, and reimbursement considerations. Based on distribution channel, direct commercial models and distributor networks shape sales cadence, service agreements, and training delivery. Based on procedure approach, bilateral and unilateral procedural strategies influence device configurability, inventory planning, and procedural time, all of which feed back into purchasing decisions and clinical pathway design.

Regional dynamics across regulatory frameworks clinical infrastructure and reimbursement landscapes that determine differentiated adoption pathways and commercial strategies

Regional dynamics create differentiated opportunities and constraints that influence regulatory pathways, clinical adoption, and commercial strategy. In the Americas, mature reimbursement frameworks, established interventional cardiology and nephrology networks, and concentration of clinical trial activity support rapid translation of evidence into practice, while healthcare purchasers in integrated delivery systems tend to prioritize total cost of care and procedural throughput. In contrast, regulatory clearance processes and payer engagement in Europe Middle East and Africa exhibit greater heterogeneity, with pockets of advanced clinical adoption in centers of excellence alongside variable reimbursement timelines and sensitivity to cost containment, which encourages adoption strategies that emphasize health economic evidence and regional KOL advocacy.

Asia Pacific presents a complex mix of high volume potential, varying regulatory maturity, and rapid investment in hospital capacity, where localized manufacturing and partnerships can accelerate access. Across regions, infrastructure for ambulatory care, availability of trained interventionalists, and payer willingness to support novel procedures form the essential determinants of uptake. Consequently, companies must align product configurations, clinical evidence generation, and commercial models to regional realities, investing in tailored health economic dossiers in some geographies while focusing on procedural training and outcomes registries in others. Cross regional collaboration and knowledge transfer can expedite the diffusion of best practices, but must be underpinned by culturally and systemically appropriate deployment plans.

Strategic company level behaviors focusing on clinical evidence differentiation integrated service offerings and resilient manufacturing to accelerate adoption and commercialization

Key competitive behaviors among device developers and ecosystem participants center on evidence generation, differentiated technology stacks, and channel partnerships that enable rapid clinical uptake. Industry leaders are prioritizing randomized clinical programs that articulate durable outcomes and patient subgroups most likely to benefit, while simultaneously investing in next generation catheter designs, energy modulation algorithms, and adjunctive imaging to improve procedural precision. Strategic alliances between device developers, clinical research organizations, and health systems are increasingly common, enabling multicenter registries and real world evidence programs that complement pivotal trials and accelerate payor discussions.

On the commercial front, firms are refining value propositions by bundling devices with training, procedure support, and postprocedure monitoring services to reduce barriers to adoption among ambulatory and hospital customers. Manufacturing optimization, including qualification of secondary suppliers and selective regionalization of production, is being pursued to reduce lead times and hedge against trade policy volatility. There is a clear premium on companies that can align engineering agility with robust clinical programs and scalable go to market models, as these capabilities shorten the path from regulatory clearance to routine clinical use. For stakeholders evaluating partnerships or acquisitions, the most compelling assets are those that combine clear clinical differentiation with executable commercialization strategies and defensible supply chain designs.

Actionable multi dimensional recommendations for clinical evidence investment supply chain resilience training commercialization and payer engagement to drive sustainable adoption

Industry leaders should pursue a coordinated strategy that addresses clinical credibility, supply chain resilience, and payer engagement in parallel. First, invest in targeted clinical programs that refine patient selection and demonstrate clinically meaningful endpoints tied to downstream cost avoidance, thereby supporting payer conversations and institutional adoption. Second, diversify sourcing and consider regional assembly or manufacturing to mitigate tariff exposure and shorten lead times, while maintaining quality systems and regulatory compliance across sites. Third, design product portfolios with procedural efficiency in mind to facilitate adoption in ambulatory settings, reducing hospital resource utilization and aligning with value based procurement models.

Additionally, prioritize scalable training and proctoring programs that enable rapid credentialing of interventionalists and allied support staff, and pair device launches with strong postmarketing surveillance and real world evidence initiatives to sustain clinical confidence. Commercial teams should craft flexible distribution approaches that combine direct relationships for strategic accounts with distributor partnerships for regional breadth, and negotiate service agreements that capture long term value through disposables, software updates, or education. Finally, engage payers early with robust health economic models and scenario analyses to secure pathways to reimbursement that reflect both clinical benefit and system level efficiency gains, ensuring that commercial access is synchronized with clinical adoption timelines.

Transparent mixed methods research approach combining systematic evidence review clinician interviews and operational analysis to produce validated strategic insights

The research underpinning this executive summary integrates systematic literature synthesis, expert interviews, and triangulation of primary and secondary sources to ensure robust, actionable insights. The methodology combined comprehensive review of peer reviewed clinical studies, regulatory submissions, and publicly available procedural guidelines with structured interviews of interventional cardiologists, nephrologists, hospital procurement leaders, and device industry executives to capture practical implementation challenges and adoption drivers. Data from device registries and procedural audits were synthesized to identify workflow constraints, device utilization patterns, and training bottlenecks, and findings were cross validated through follow up consultations with clinical experts.

Analytical approaches included thematic coding of qualitative interviews to surface recurring operational and commercial themes, alongside comparative assessment of device features, procedural steps, and distribution models to map strategic options. The research acknowledges limitations inherent in evolving clinical evidence and in the variable transparency of commercial contracts, and where direct evidence was limited, scenarios were developed in consultation with domain experts to explore plausible outcomes. Ethical safeguards were applied throughout primary research, ensuring informed consent for interviews and anonymization of proprietary operational details, while adherence to recognized standards for evidence synthesis guided reporting integrity.

Concluding synthesis emphasizing coordinated clinical evidence operational readiness and commercial alignment as prerequisites for durable adoption and impact

The collective insights presented here underscore that renal denervation devices are transitioning from investigational options to differentiated therapeutic platforms that require integrated strategies across clinical evidence, supply chain, and commercialization. As device modalities diversify across chemical, radiofrequency, and ultrasound approaches, stakeholders must focus on demonstrating consistent clinical benefit within clearly defined patient populations and aligning product design with real world procedural workflows. The interplay between regional regulatory expectations, payer requirements, and site of service economics will continue to shape which technologies advance towards routine clinical use.

Decision makers should therefore prioritize actions that reduce adoption friction: invest in rigorous outcomes research, design devices and service offerings for ambulatory environments, and secure resilient supply chains that preempt tariff driven disruptions. By coordinating clinical, operational, and commercial plans, organizations can convert technical differentiation into sustainable clinical adoption, delivering improved patient outcomes while managing institutional cost pressures. The path forward favors those who combine clinical conviction with pragmatic implementation capabilities and who engage stakeholders across the care continuum to ensure that evidence, access, and training converge to support durable adoption.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Renal Denervation Devices Market, by Product Type

  • 8.1. Chemical
  • 8.2. Radiofrequency
    • 8.2.1. Monopolar
    • 8.2.2. Multipolar
  • 8.3. Ultrasound
    • 8.3.1. Endovascular
    • 8.3.2. External

9. Renal Denervation Devices Market, by Energy Source

  • 9.1. Chemical
  • 9.2. Radiofrequency
  • 9.3. Ultrasound

10. Renal Denervation Devices Market, by Procedure

  • 10.1. Bilateral
  • 10.2. Unilateral

11. Renal Denervation Devices Market, by Application

  • 11.1. Chronic Kidney Disease
  • 11.2. Heart Failure
  • 11.3. Hypertension

12. Renal Denervation Devices Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Cardiac Centers
  • 12.3. Clinics
  • 12.4. Hospitals

13. Renal Denervation Devices Market, by Distribution Channel

  • 13.1. Direct
  • 13.2. Distributor

14. Renal Denervation Devices Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Renal Denervation Devices Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Renal Denervation Devices Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Renal Denervation Devices Market

18. China Renal Denervation Devices Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Ablative Solutions, Inc.
  • 19.7. AngioDynamics, Inc.
  • 19.8. Biosense Webster, Inc.
  • 19.9. Boston Scientific Corporation
  • 19.10. Cardionovum GmbH
  • 19.11. Cordis Corporation
  • 19.12. DeepQure Inc.
  • 19.13. Johnson & Johnson Services, Inc.
  • 19.14. Medinol Ltd.
  • 19.15. Medtronic plc
  • 19.16. Mercator MedSystems, Inc.
  • 19.17. Miracor Medical SA
  • 19.18. Otsuka Medical Devices Co., Ltd.
  • 19.19. ReCor Medical, Inc.
  • 19.20. Renal Dynamics Ltd.
  • 19.21. Shanghai Golden Leaf MedTec Co., Ltd.
  • 19.22. Shanghai Wisegain Medical Devices Co., Ltd.
  • 19.23. SoniVie Ltd.
  • 19.24. SoundPipe Therapeutics LLC
  • 19.25. Suzhou SyMap Medical Devices Co., Ltd.
  • 19.26. Symap Medical Co., Ltd.
  • 19.27. Symple Surgical, Inc.
  • 19.28. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RENAL DENERVATION DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RENAL DENERVATION DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY ENERGY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY PROCEDURE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES RENAL DENERVATION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA RENAL DENERVATION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY CHEMICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY CHEMICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY CHEMICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY RADIOFREQUENCY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY RADIOFREQUENCY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY RADIOFREQUENCY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY MONOPOLAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY MONOPOLAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY MONOPOLAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY MULTIPOLAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY MULTIPOLAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY MULTIPOLAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY ENDOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY ENDOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY ENDOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY EXTERNAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY EXTERNAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY EXTERNAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY ENERGY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY CHEMICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY CHEMICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY CHEMICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY RADIOFREQUENCY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY RADIOFREQUENCY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY RADIOFREQUENCY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY BILATERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY BILATERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY BILATERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY UNILATERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY UNILATERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY UNILATERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY DIRECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY DIRECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY DIRECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY DISTRIBUTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY DISTRIBUTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS RENAL DENERVATION DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS RENAL DENERVATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS RENAL DENERVATION DEVICES MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS RENAL DENERVATION DEVICES MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS RENAL DENERVATION DEVICES MARKET SIZE, BY ENERGY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS RENAL DENERVATION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS RENAL DENERVATION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS RENAL DENERVATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS RENAL DENERVATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA RENAL DENERVATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA RENAL DENERVATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA RENAL DENERVATION DEVICES MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA RENAL DENERVATION DEVICES MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA RENAL DENERVATION DEVICES MARKET SIZE, BY ENERGY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA RENAL DENERVATION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA RENAL DENERVATION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA RENAL DENERVATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA RENAL DENERVATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA RENAL DENERVATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA RENAL DENERVATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA RENAL DENERVATION DEVICES MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA RENAL DENERVATION DEVICES MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA RENAL DENERVATION DEVICES MARKET SIZE, BY ENERGY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA RENAL DENERVATION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA RENAL DENERVATION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA RENAL DENERVATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA RENAL DENERVATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA RENAL DENERVATION DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA RENAL DENERVATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA RENAL DENERVATION DEVICES MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA RENAL DENERVATION DEVICES MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA RENAL DENERVATION DEVICES MARKET SIZE, BY ENERGY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA RENAL DENERVATION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA RENAL DENERVATION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA RENAL DENERVATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA RENAL DENERVATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE RENAL DENERVATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE RENAL DENERVATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE RENAL DENERVATION DEVICES MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE RENAL DENERVATION DEVICES MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE RENAL DENERVATION DEVICES MARKET SIZE, BY ENERGY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE RENAL DENERVATION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE RENAL DENERVATION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE RENAL DENERVATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE RENAL DENERVATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST RENAL DENERVATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST RENAL DENERVATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST RENAL DENERVATION DEVICES MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST RENAL DENERVATION DEVICES MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST RENAL DENERVATION DEVICES MARKET SIZE, BY ENERGY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST RENAL DENERVATION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST RENAL DENERVATION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST RENAL DENERVATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST RENAL DENERVATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA RENAL DENERVATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA RENAL DENERVATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA RENAL DENERVATION DEVICES MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA RENAL DENERVATION DEVICES MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA RENAL DENERVATION DEVICES MARKET SIZE, BY ENERGY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA RENAL DENERVATION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA RENAL DENERVATION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA RENAL DENERVATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA RENAL DENERVATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC RENAL DENERVATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC RENAL DENERVATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC RENAL DENERVATION DEVICES MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC RENAL DENERVATION DEVICES MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC RENAL DENERVATION DEVICES MARKET SIZE, BY ENERGY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC RENAL DENERVATION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC RENAL DENERVATION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC RENAL DENERVATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC RENAL DENERVATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN RENAL DENERVATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN RENAL DENERVATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN RENAL DENERVATION DEVICES MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN RENAL DENERVATION DEVICES MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN RENAL DENERVATION DEVICES MARKET SIZE, BY ENERGY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN RENAL DENERVATION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN RENAL DENERVATION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN RENAL DENERVATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN RENAL DENERVATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. GCC RENAL DENERVATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC RENAL DENERVATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC RENAL DENERVATION DEVICES MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 159. GCC RENAL DENERVATION DEVICES MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 160. GCC RENAL DENERVATION DEVICES MARKET SIZE, BY ENERGY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 161. GCC RENAL DENERVATION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 162. GCC RENAL DENERVATION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. GCC RENAL DENERVATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. GCC RENAL DENERVATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION RENAL DENERVATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION RENAL DENERVATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION RENAL DENERVATION DEVICES MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION RENAL DENERVATION DEVICES MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION RENAL DENERVATION DEVICES MARKET SIZE, BY ENERGY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION RENAL DENERVATION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION RENAL DENERVATION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION RENAL DENERVATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION RENAL DENERVATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS RENAL DENERVATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS RENAL DENERVATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS RENAL DENERVATION DEVICES MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS RENAL DENERVATION DEVICES MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS RENAL DENERVATION DEVICES MARKET SIZE, BY ENERGY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS RENAL DENERVATION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS RENAL DENERVATION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS RENAL DENERVATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS RENAL DENERVATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. G7 RENAL DENERVATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 RENAL DENERVATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 RENAL DENERVATION DEVICES MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 186. G7 RENAL DENERVATION DEVICES MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 187. G7 RENAL DENERVATION DEVICES MARKET SIZE, BY ENERGY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 188. G7 RENAL DENERVATION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 189. G7 RENAL DENERVATION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. G7 RENAL DENERVATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. G7 RENAL DENERVATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. NATO RENAL DENERVATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO RENAL DENERVATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO RENAL DENERVATION DEVICES MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 195. NATO RENAL DENERVATION DEVICES MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 196. NATO RENAL DENERVATION DEVICES MARKET SIZE, BY ENERGY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 197. NATO RENAL DENERVATION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 198. NATO RENAL DENERVATION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. NATO RENAL DENERVATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. NATO RENAL DENERVATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL RENAL DENERVATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES RENAL DENERVATION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES RENAL DENERVATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES RENAL DENERVATION DEVICES MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES RENAL DENERVATION DEVICES MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES RENAL DENERVATION DEVICES MARKET SIZE, BY ENERGY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES RENAL DENERVATION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES RENAL DENERVATION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES RENAL DENERVATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES RENAL DENERVATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA RENAL DENERVATION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA RENAL DENERVATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA RENAL DENERVATION DEVICES MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA RENAL DENERVATION DEVICES MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA RENAL DENERVATION DEVICES MARKET SIZE, BY ENERGY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA RENAL DENERVATION DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA RENAL DENERVATION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA RENAL DENERVATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA RENAL DENERVATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)